Studio clinico NCT06561386 · Non-small Cell Lung Cancer
Ricerca oncologica
26/10/2026
NCT06561386 — risulta «in reclutamento» su ClinicalTrials.gov.
Studio clinico NCT06561386 (fase III) risulta «in reclutamento» su ClinicalTrials.gov.
Patologia: Non-small Cell Lung Cancer · Interventi registrati: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin · Date registrate (fonte): 2024-10-07, 2030-07-30, 2024-08-20, 2026-10-23.
Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%